Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C.

Contrast media & molecular imaging - 1 Jan 2022

Yu Jiao, Xu Dong

Abstract excerpt

This article discusses the clinical value of Pegylated Interferon (PEG-IFN) α-2a combined with entecavir or tenofovir in the treatment of Chronic Hepatitis B (CHB) genotype C patients. 78 patients with CHB genotype C were divided into three groups: control group, entecavir group, and tenofovir group according to different treatment methods. The efficacy and adverse reaction (AR) of the three groups are observed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Guanine
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Polyethylene Glycols

Share to Recombinant Proteins

Share to Tenofovir

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 36247853
DOI: 10.1155/2022/7623832
PMCID: PMC9534658

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C.PMID 36247853Read ↗

[Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: a comparative study].Semantic proximity Read ↗

Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.Semantic proximity Read ↗

Peginterferon and ribavirin treatment for hepatitis C virus infection.Semantic proximity Read ↗

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.Semantic proximity Read ↗

Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea.Semantic proximity Read ↗

Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis.Semantic proximity Read ↗

Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes.Semantic proximity Read ↗

Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy.Semantic proximity Read ↗

Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B.Semantic proximity Read ↗

Tenofovir Versus Entecavir for the Treatment of Acute-on-Chronic Liver Failure due to Reactivation of Chronic Hepatitis B With Genotypes B and C.Semantic proximity Read ↗

Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.Semantic proximity Read ↗

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.